skip to Global Navigation Bar skip to main content

homeHome > About Us > Recruitment > News


News Content
Daewoong Pharmaceutical’s ‘Nabota’ secured application to blepharospasm.
Date 2019-06-24 Hit 2047
News List
Prev Daewoong Pharmaceutical initiates development of new medication for hearing impairment (First in Class) with Yonsei University based on the ion channel platform technology.
Next DWN12088, Daewoong Pharmaceutical’s new drug for pulmonary fibrosis, enters global clinical studies phase 1.